Mitragotri.jpg

Prof. Mitragotri has made groundbreaking contributions to the field of biological barriers and drug delivery. His research has advanced fundamental understanding of biological barriers and has led to the development of new materials as well as technologies for diagnosis and treatment of various ailments including diabetes, cancer, cardiovascular diseases, skin conditions and infections, among others. Many of his technologies have advanced to human clinical studies and products. At the same time, fundamental understanding developed through his research has advanced the understanding of the biology of barriers in the human body. 

Core Faculty Member, Wyss Institute for Biologically Inspired Engineering

Area Chair for Bioengineering

Dr. Samir Mitragotri, PhD

Richardson.jpg

Dr. Richardson is an infectious disease physician and critical medical anthropologist. He conducts biosocial research on epidemic disease in sub-Saharan Africa. Richardson previously served as the clinical lead for Partners in Health’s Ebola response in Kono District, Sierra Leone, and in 2016, was awarded a Harvard KL2 career development award to study the social epidemiology of Ebola virus infection. Since then, he was selected to be part of the Wellcome Trust Ebola Expert Working Group and has published many original research articles and commentaries in journals such as The Lancet Global Health, PLOS Neglected Tropical Diseases, and The Journal of Infectious Diseases.

Assistant Professor of Global Health and Social Medicine, Harvard Medical School

Associate Physician, Brigham and Women’s Hospital

Dr. Eugene Richardson, MD, PhD

Sabeti.jpg

Dr. Sabeti is a computational geneticist with expertise developing algorithms to detect genetic signatures of adaption in humans and the microbial organisms that infect humans. Her lab’s key research areas include: (1) Developing analytical methods to detect and investigate evolution in the genomes of humans and other species (2) Examining host and viral genetic factors driving disease susceptibility to the devastating and deadly diseases in West Africa, Ebola Virus Disease and Lassa hemorrhagic fever. (3) Investigating the genomes of microbes, including Lassa virus, Ebola virus, Plasmodium falciparum malaria, Vibrio cholera, and Mycobacterioum tuberculosis to help in the development of intervention strategies. (4) Determining the microbial cause of undiagnosed acute febrile illness.

Dr. Sabeti completed her undergraduate degree at MIT, her graduate work at Oxford University as a Rhodes Scholar, and her medical degree summa cum laude from Harvard Medical School as a Soros Fellow. Dr. Sabeti is a World Economic Forum (WEF) Young Global Leader and a National Geographic Emerging Explorer, and was named a TIME magazine ‘Person of the Year’ as one of the Ebola fighters. Her awards included the Smithsonian American Ingenuity Award for Natural Science, the Vilcek Prize for Creative Promise, the NIH Innovator Award, the Packard Fellowship, and an Ellis Island Medal of Honor. She has served on the MIT Board of Trustees and the National Academy of Sciences Committee on Women in Science, Medicine, and Engineering. Dr. Sabeti is also the lead singer and co-song writer of the rock band Thousand Days.

Assistant Professor of Global Health and Social Medicine, Harvard Medical School

Investig

Dr. Pardis Sabeti, MD, M.Phil

Dr. Kesselheim graduated from Harvard College and received his postgraduate training at the University of Pennsylvania School of Medicine and Law School, and most recently at the Harvard School of Public Health. He is Board Certified in Internal Medicine, and serves as a primary care physician at the Phyllis Jen Center for Primary Care at BWH. His research focuses on the effects of intellectual property laws and regulatory policies on pharmaceutical development, the drug approval process, and the costs, availability, and use of prescription drugs both domestically and in resource-poor settings. He has also investigated how other issues at the intersection of law and public health can affect the health care system, including health care fraud, expert testimony in malpractice cases, and insurance reimbursement practices. He is a member of the New York State Bar and is a Patent Attorney.

Within the Division, Dr. Kesselheim leads the Program On Regulation, Therapeutics, And Law (PORTAL), an interdisciplinary research core focusing on intersections among prescription drugs and medical devices, patient health outcomes, and regulatory practices and the law. 

Associate Professor of Medicine, Harvard Medical School

Faculty Member, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital

Dr. Aaron Kesselheim, MD, JD, MPH

Darrow.jpg

Dr. Darrow holds degrees in biological sciences / genetics, law, and business from Cornell, Duke, and Boston College, respectively, as well as a research doctorate in pharmaceutical policy and intellectual property theory from Harvard Law School, where he also completed the LL.M. program. He has been qualified as a patent attorney since 2002. After admission to the California bar in 2001, Dr. Darrow worked on pharmaceutical litigation matters at Wiley Rein & Fielding in Washington, DC, taught on the business law faculties of three universities (2004-2014), served as a senior law clerk for a federal appellate judge, and explored the relationship between innovation policy and global health in service to the World Trade Organization, the World Health Organization, and the World Intellectual Property Organization. His scholarship on health policy and intellectual property has appeared in the British Medical Journal, the New England Journal of Medicine, the Journal of Law, Medicine & Ethics; the Stanford Technology Law Review; the Yale Journal of Health Policy Law & Ethics; and Health Affairs, among many others, and he has testified before a committee of the Massachusetts legislature on an emerging issue of law and technology.

Faculty, Harvard Medical School

Member, Program on Regulation, Therapeutics, and Law, Brigham & Women's Hospital

Dr. Jonathan Darrow, SJD, JD, MBA, LLM

Keshsavjee.jpg

Dr. Keshavjee is a professor in the Department of Global Health and Social Medicine and Department of Medicine at Harvard Medical School. He also serves as a physician in the Division of Global Health Equity at the Brigham and Women’s Hospital. He conducted doctoral research in medical anthropology at Harvard University on the health transition in post-Soviet Tajikistan. He has worked with the Division of Global Health Equity and Partners In Health on the implementation of a multidrug-resistant tuberculosis (MDR-TB) treatment program in Tomsk, Russia. Between 2000 and 2008, Dr. Keshavjee set up a program to treat patients co-infected with HIV and MDR-TB in Lesotho. Between 2007 and 2010, Dr. Keshavjee served as the chair of the Green Light Committee Initiative, a Stop TB Partnership/WHO initiative which helps countries gain access to high-quality second-line anti-TB drugs so they can provide treatment for people with MDR-TB in line with the WHO guidelines, the latest scientific evidence, and country experiences. 

Director, Harvard Center for Global Health Delivery - Dubai

Faculty, Department of Global Health and Social Medicine, Harvard Medical School

Physician, Division of Global Health Equity, Brigham & Women's Hospital

Dr. Salmaan Keshavjee, MD, PhD, ScM

© 2019 by Harvard Global Alliance for Medical Innovation